目的 探討腎康寧膠囊聯(lián)合嗎替麥考酚酯治療慢性腎小球腎炎的臨床療效。方法 選擇2020年2月—12月在河南科技大學(xué)第一附屬醫(yī)院治療的96例慢性腎小球腎炎患者為研究對(duì)象，根據(jù)用藥的差別分為對(duì)照組和治療組，每組各48例。對(duì)照組口服嗎替麥考酚酯片，1 g/次，2次/d；治療組在對(duì)照組基礎(chǔ)上口服腎康寧膠囊，5粒/次，3次/d。兩組患者均治療3個(gè)月。觀察兩組患者臨床療效，比較治療前后兩組患者中醫(yī)癥狀改善時(shí)間，腎功能指標(biāo)血肌酐（Scr）、尿素氮（BUN）和24 h尿蛋白定量（24 h Upro）水平及血清結(jié)締組織生長(zhǎng)因子（CTGF）、白細(xì)胞誘素-1（Lkn-1）、金屬蛋白酶組織抑制劑-1（TIMP-1）、血管內(nèi)皮生長(zhǎng)因子（VEGF）水平和胱抑素C（Cys-C）水平。結(jié)果 經(jīng)治療，對(duì)照組和治療組總有效率分別為81.25%、97.92%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。經(jīng)治療，治療組中醫(yī)癥狀改善時(shí)間上明顯早于對(duì)照組（P<0.05）。經(jīng)治療，兩組BUN、SCr、24 h Upro水平均下降（P<0.05），且治療組更明顯（P<0.05）。經(jīng)治療，兩組患者血清CTGF、Lkn-1、TIMP-1、Cys-C、VEGF水平均明顯降低（P<0.05），且治療組降低更顯著（P<0.05）。結(jié)論 腎康寧膠囊聯(lián)合嗎替麥考酚酯片治療慢性腎小球腎炎可有效改善患者臨床癥狀，改善患者腎功能，促進(jìn)機(jī)體細(xì)胞因子水平改善。

Objective To investigate the clinical efficacy of Shenkangning Capsules combined with mycophenolate mofetil in treatment of chronic glomerulonephritis. Methods Patients (96 cases) with chronic glomerulonephritis in the First Affiliated Hospital of Henan University of Science and Technology from February 2020 to December 2020 were divided into control and treatment groups according to the difference of medication, and each group had 48 cases. Patients in the control group were po administered with Mycophenolate Mofetil Tablets, 1 g/time, twice daily. Patients in the treatment group were po administered with Shenkangning Capsules, 5 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical evaluation was evaluated, the improvement time of TCM symptoms, renal function indexes Scr, BUN, and 24 h Upro, and the levels of serum CTGF, Lkn-1, TIMP-1, VEGF, and Cys-C in two groups before and after treatment were compared. Results After treatment, the clinical effective rates of the control group and the treatment group were 81.25% and 97.92%, respectively (P<0.05). After treatment, the improvement time of TCM symptoms in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the levels of BUN, Scr, and 24 h Upro were significantly decreased in two groups (P<0.05), especially in the treatment group (P<0.05). After treatment, the serum levels of CTGF, Lkn-1, TIMP-1, Cys-C, and VEGF were significantly decreased in two groups (P<0.05), especially in the treatment group (P<0.05). Conclusion Shenkangning Capsules combined with mycophenolate mofetil in treatment of chronic glomerulonephritis can effectively improve the clinical symptoms, improve the renal function, and promote the improvement of the level of cytokines.

R983

河南省科技攻關(guān)計(jì)劃項(xiàng)目（152101309216）